Q-omics provides the consensus-scored ZSCAN4 profile across patient tissues and cancer cell-line models. ZSCAN4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZSCAN4 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, ZSCAN4 RNA expression shows 14,270 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BRCA, and THYM as cancer lineages where ZSCAN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN4 survival associations across molecular data types. ZSCAN4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN4 RNA expression–survival associations across cancer types. High ZSCAN4 expression shows unfavorable associations in MESO, but favorable associations in ACC, THCA, OV, KIRC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for ZSCAN4 RNA expression.
This table summarizes ZSCAN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZSCAN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN4 shows lower tumor expression in BRCA, KIRP and READ and higher tumor expression in KIRC, THCA and PAAD. The BRCA box plot shows higher ZSCAN4 RNA expression in normal versus tumor tissue (log2 FC = −0.197, t-test p < 0.001).
This table shows molecular features associated with ZSCAN4 in patient tissues and cancer cell lines. In patient samples, ZSCAN4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
